A PYMNTS Company

UK: Companies Vectura and Skyepharma agree £441m merger

By  |  March 16, 2016

Vectura and Skyepharma have agreed a £441m merger to create a more powerful mid-sized UK pharmaceuticals group focused on respiratory drugs.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Both companies make treatments for asthma and other breathing difficulties and together would have a market capitalisation of just over £1bn based on their respective valuations on Tuesday, writes Andrew Ward.

    Their combined revenues were £153.9m, with operating profits £50.5m based on each company’s most recent full-year results.

    The enlarged company will be run by James Ward-Lilley, Vectura chief executive and a former senior AstraZeneca executive. Bruno Angelici, Vectura’s chairman, will also keep his role. Peter Grant, Skyepharma’s CEO, will depart but the company’s chairman, Frank Condella, will stay on as deputy to Mr Angelici.

    Full Content: The Financial Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.